A critical role for hepatic protein arginine methyltransferase 1 isoform 2 in glycemic control

• Published in: The FASEB journal Vol. 34; no. 11; p. 14863
• Main Authors: Ma, Yingxu, Liu, Shanshan, Jun, Heejin, Wang, Jine, Fan, Xiaoli, Li, Guobing, Yin, Lei, Rui, Liangyou, Weinman, Steven A, Gong, Jianke, Wu, Jun
• Format: Journal Article
• Language: English
• Published: United States 01.11.2020
• Subjects: Animals; Cells, Cultured; Gain of Function Mutation; Glucagon - metabolism; Gluconeogenesis; Glucose - metabolism; Hep G2 Cells; Hepatocytes - metabolism; Humans; Hyperglycemia - genetics; Hyperglycemia - metabolism; Mice; Mice, Inbred C57BL; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha - metabolism; Protein Isoforms - genetics; Protein Isoforms - metabolism; Protein-Arginine N-Methyltransferases - genetics; Protein-Arginine N-Methyltransferases - metabolism; PRMT1 variant 2; glycemic control; diabetic hyperglycemia; liver function
• ISSN: 1530-6860
• DOI: 10.1096/fj.202001061R

Appropriate control of hepatic gluconeogenesis is essential for the organismal survival upon prolonged fasting and maintaining systemic homeostasis under metabolic stress. Here, we show protein arginine methyltransferase 1 (PRMT1), a key enzyme that catalyzes the protein arginine methylation process, particularly the isoform encoded by Prmt1 variant 2 (PRMT1V2), is critical in regulating gluconeogenesis in the liver. Liver-specific deletion of Prmt1 reduced gluconeogenic capacity in cultured hepatocytes and in the liver. Prmt1v2 was expressed at a higher level compared to Prmt1v1 in hepatic tissue and cells. Gain-of-function of PRMT1V2 clearly activated the gluconeogenic program in hepatocytes via interactions with PGC1α, a key transcriptional coactivator regulating gluconeogenesis, enhancing its activity via arginine methylation, while no effects of PRMT1V1 were observed. Similar stimulatory effects of PRMT1V2 in controlling gluconeogenesis were observed in human HepG2 cells. PRMT1, specifically PRMT1V2, was stabilized in fasted liver and hepatocytes treated with glucagon, in a PGC1α-dependent manner. PRMT1, particularly Prmt1v2, was significantly induced in the liver of streptozocin-induced type 1 diabetes and high fat diet-induced type 2 diabetes mouse models and liver-specific Prmt1 deficiency drastically ameliorated diabetic hyperglycemia. These findings reveal that PRMT1 modulates gluconeogenesis and mediates glucose homeostasis under physiological and pathological conditions, suggesting that deeper understanding how PRMT1 contributes to the coordinated efforts in glycemic control may ultimately present novel therapeutic strategies that counteracts hyperglycemia in disease settings.